Glycotest Overview
- Founded
- 2012
- Status
- Private
- Employees
- 2
- Latest Deal Type
- Series A
- Latest Deal Amount
- $10M
- Investors
- 2
Glycotest General Information
Description
Operator of a liver diagnostics platform intended to commercialize blood tests for life-threatening liver cancers and fibrosis-cirrhosis. The company's platform provides non-invasive blood tests based on proprietary serum biomarkers, biomarker panels and assay technology that exploit novel sugar-based disease signal chemistry, enabling patients with serious liver disease to avail novel clinical laboratory testing services and experience early detection of liver cancer and chronic liver disease.
Contact Information
Website
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Diagnostic Equipment
Other Industries
Laboratory Services (Healthcare)
Biotechnology
Primary Office
- 613 Schiller Avenue
- Suite 817
- Merion, PA 19066
- United States
+1 (484) 000-0000
Glycotest Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Corporate (Series A) | 05-Feb-2019 | $10M | 0000 | 0000 | Completed | Clinical Trials - Phase 3 |
| 3. Buyout/LBO | 31-Dec-2016 | 00.000 | 00.00 | 00.000 | Completed | Clinical Trials - General |
| 2. Accelerator/Incubator | 05-Jun-2012 | $500K | $1.3M | Completed | Stealth | |
| 1. Later Stage VC | 25-May-2012 | $801K | $801K | Completed | Stealth |
Glycotest Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A | 00,000,000 | 00.000000 | 00 | 00.00 | 00.00 | 00 | 00.00 | 00.000 |
Glycotest Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Operator of a liver diagnostics platform intended to commercialize blood tests for life-threatening liver cancers and fi
Diagnostic Equipment
Merion, PA
2
As of 2020
0000
000
0000-00-00
00000000000
0000
0000
eprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat
0000000000 000000
Matsuyama, Japan
0000
As of 0000
0000
t ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco l
000000000 (000)
Enid, OK
00
As of 0000
Add Comparison
PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.
Request a free trialGlycotest Competitors (2)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Fuji | Corporation | Matsuyama, Japan | 0000 | |||
| 0000 | Corporation | Enid, OK | 00 |
Glycotest Executive Team (4)
Glycotest Board Members (9)
| Name | Representing | Role | Since |
|---|---|---|---|
| Ilian Iliev Ph.D | Self | Board Member | 000 0000 |
| Jing Yu Ph.D | Fosun Pharma | Board Member | 000 0000 |
| Stephen Smith | NetScientific | Board Member | 000 0000 |
| Yuejian Zhang | Fosun Pharma | Board Member | 000 0000 |
Glycotest Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %ile
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trialGlycotest Investors (2)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| Fosun Pharma | Corporation | Majority | 000 0000 | 000000 0 | |
| NetScientific | Venture Capital | Minority | 000 0000 | 000000 0 |